Synergistic effects of immunotherapy and adjunctive therapies in prostate cancer management DOI Creative Commons
Jie Chen,

Na Ma,

Bo Chen

et al.

Critical Reviews in Oncology/Hematology, Journal Year: 2024, Volume and Issue: 207, P. 104604 - 104604

Published: Dec. 26, 2024

In recent years, cancer immunotherapy has received widespread attention due to significant tumor clearance in some malignancies. Various approaches, including vaccines, immune checkpoint inhibitors, oncolytic virotherapy, bispecific T cell engagers, and adoptive transfer, have completed or are undergoing clinical trials for prostate cancer. Despite blockade's extraordinary effectiveness treating a variety of cancers, targeted treatment using the system is still its infancy. Multiple factors heterogeneity cancer, cold microenvironment, low level neoantigens, contribute poor response. Significant effort being devoted improving immune-based therapy. Recently, several key discoveries demonstrate that agents may be used promise better prognosis patients as part combination strategies with other targeting tumor-associated mechanism resistance. Here, this review comprehensively examines advancements exploring potential synergistic effects when combined modalities enhance efficacy.

Language: Английский

Exploring the relationship between anastasis and mitochondrial ROS-mediated ferroptosis in metastatic chemoresistant cancers: a call for investigation DOI Creative Commons
Yu Cao, Chang Lu, Narasimha M. Beeraka

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: July 2, 2024

Ferroptosis induces significant changes in mitochondrial morphology, including membrane condensation, volume reduction, cristae alteration, and outer rupture, affecting function cellular fate. Recent reports have described the intrinsic iron metabolism its intricate connection to ferroptosis, a kind of cell death characterized by dependence oxidative stress regulation. Furthermore, updated molecular insights elucidated significance mitochondria ferroptosis implications various cancers. In context cancer therapy, understanding dual role anastasis chemoresistance is crucial. Targeting pathways involved may enhance efficacy inducers, providing synergistic approach overcome chemoresistance. Research into how DNA damage response (DDR) proteins, metabolic changes, redox states interact during can offer new designing combinatorial therapeutic regimens against several cancers associated with stemness. These treatments could potentially inhibit while simultaneously inducing thereby reducing likelihood cells evading developing resistance chemotherapy. The objective this study explore interplay between anastasis, EMT chemoresistance, immunotherapeutics better understand their collective impact on therapy outcomes. We searched public research databases google scholar, PubMed, relemed, national library medicine related topic. review, we discussed tricarboxylic acid cycle glycolysis implicated modulating adding complexity regulatory mechanisms. Additionally, reactive oxygen species (ROS) electron transport chain (ETC) has garnered attention. Lipid metabolism, particularly involving GPX4 System Xc- plays both progression cancer. There need investigate clinical Integrating strategies targeting exploring potential synergy immunotherapy represent promising avenues for advancing chemoresistant treatment. Understanding among mitochondria, ROS, vital oncology, revolutionizing personalized treatment drug development.

Language: Английский

Citations

6
Unleashing novel horizons in advanced prostate cancer treatment: investigating the potential of prostate specific membrane antigen-targeted nanomedicine-based combination therapy DOI Creative Commons
Mingze He, Yu Cao,

Changliang Chi

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Sept. 19, 2023

Prostate cancer (PCa) is a prevalent malignancy with increasing incidence in middle-aged and older men. Despite various treatment options, advanced metastatic PCa remains challenging poor prognosis limited effective therapies. Nanomedicine, its targeted drug delivery capabilities, has emerged as promising approach to enhance efficacy reduce adverse effects. Prostate-specific membrane antigen (PSMA) stands one of the most distinctive highly selective biomarkers for PCa, exhibiting robust expression cells. In this review, we explore applications PSMA-targeted nanomedicines management. Our primary objective bridge gap between cutting-edge nanomedicine research clinical practice, making it accessible medical community. We discuss mainstream strategies including chemotherapy, radiotherapy, immunotherapy, context nanomedicines. Additionally, elucidate novel concepts such photodynamic photothermal therapies, along nano-theragnostics. present content clear manner, appealing general physicians, those backgrounds biochemistry bioengineering. The review emphasizes potential benefits enhancing efficiency improving patient outcomes. While use nano-drug demonstrated results, further investigation required comprehend precise mechanisms action, pharmacotoxicity, long-term By meticulous optimization combination PSMA ligands, horizon nanomedicine-based therapy could bring renewed hope patients PCa.

Language: Английский

Citations

13
Exploring Immunological Effects and Novel Immune Adjuvants in Immunotherapy for Salivary Gland Cancers DOI Open Access
Ryosuke Sato,

Hidekiyo Yamaki,

Hiroki Komatsuda

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(6), P. 1205 - 1205

Published: March 19, 2024

Salivary gland cancer (SGC) is rare and comprises over 20 histological subtypes. Recently, clinical experience regarding immunotherapies for SGCs has been accumulating, yet their efficacy remains controversial. Understanding the tumor microenvironment (TME), including expression of immune checkpoint molecules in SGC, crucial to optimizing immunotherapy. In this review, we demonstrate that high-grade mucoepidermoid carcinoma salivary duct generally exhibit immune-hot TME with high cell infiltration, frequent genetic mutations, robust molecule expression. contrast, adenoid cystic carcinomas an immune-cold TME. While reported inhibitors (ICIs) poor, several studies showed promising ICIs, objective response rate ranging from 20.0–33.3%, indicating ICIs might be beneficial a specific population SGC. Molecule-targeted therapies anti-human epidermal growth factor receptor 2 anti-androgen have shown against Recent evidence indicates these could targets antigen-specific chimeric antigen receptor-T therapy vaccines. This review discusses current understanding future directions SGCs, ongoing trials.

Language: Английский

Citations

4
Evidence-Based Recommendations on the Use of Immunotherapies and Monoclonal Antibodies in the Treatment of Male Reproductive Cancers DOI Creative Commons
Farhan Khalid, Zubair Hassan Bodla,

Sai Rakshith Gaddameedi

et al.

Current Oncology, Journal Year: 2025, Volume and Issue: 32(2), P. 108 - 108

Published: Feb. 14, 2025

The incidence of male reproductive cancers, including prostate, testicular, and penile has risen in recent years, raising important health concerns. Prostate cancer is the second leading cause cancer-related mortality men, while cancer, though rare, typically affects men over 60. Testicular with a lifetime risk about 0.4% most common among adolescents young adults, decreasing sharply after age 40. Traditional treatments include chemotherapy, radiation, surgery, combinations thereof, but advancements immunotherapy monoclonal antibodies are showing promising results, particularly for genitourinary cancers. These therapies, targeting immune checkpoints tumor-specific antigens, gaining traction as effective alternatives resistant cases. This review provides evidence-based recommendations on current emerging antibody highlighting future directions to optimize patient outcomes.

Language: Английский

Citations

0
Integrative approach to decipher pharmacological mechanism of Cinnamomum zeylanicum essential oil in prostate cancer DOI

Debajani Mohanty,

Sucheesmita Padhee,

Arpita Priyadarshini

et al.

Medical Oncology, Journal Year: 2025, Volume and Issue: 42(4)

Published: March 12, 2025

Language: Английский

Citations

0
Advancements in nanomedicine: Precision delivery strategies for male pelvic malignancies – Spotlight on prostate and colorectal cancer DOI Creative Commons
Guodong Yang, Yu Cao, Xinyi Yang

et al.

Experimental and Molecular Pathology, Journal Year: 2024, Volume and Issue: 137, P. 104904 - 104904

Published: May 25, 2024

Pelvic malignancies consistently pose significant global health challenges, adversely affecting the well-being of male population. It is anticipated that clinicians will continue to confront these cancers in their practice. Nanomedicine offers promising strategies revolutionize treatment pelvic by providing precise delivery methods aim improve efficacy therapeutic outcomes while minimizing side effects. Nanoparticles are designed encapsulate agents and selectively target cancer cells. They can also be loaded with theragnostic agents, enabling multifunctional capabilities.

Language: Английский

Citations

2
Autoantibodies Targeting Prostate-specific Antigen: Implications in Prostate Cancer – A Narrative Review DOI
Naina Kumar

Oncology Journal of India, Journal Year: 2024, Volume and Issue: 8(2), P. 21 - 25

Published: May 1, 2024

Abstract Prostate cancer ranks second among cancers affecting men, surpassed only by lung cancer, with predominant occurrence in men over 55 years old. Primary screening method, serum total prostate-specific antigen (PSA) test, lacks specificity as elevated PSA levels can occur benign prostate conditions and other such breast, lung, salivary gland. Furthermore, the sensitivity of prediction ranges from 9% to 33%. Consequently, there is an urgent demand for precise tests innovative therapeutic approaches cancer. This review explores emerging role autoantibodies diagnosis management, alongside development novel vaccines utilizing these antibodies against cells. Literature search spanned October 1987 September 2023 across databases including PubMed, SCOPUS, EMBASE, encompassing numerous English peer-reviewed journals. Additional data were gathered agencies, WHO ICMR, updated global Indian figures on Key terms included “Prostate incidence screening,” “Prostate-Specific antigen,” “PSA autoantibodies,” “New diagnostic techniques cancer,” “Vaccines cancer.” Hence, exhibit promising potential applications Unlike conventional test alone, combination offer enhanced 79% 84% detecting Their integration into protocols could significantly improve early detection rates enable timely intervention. marks a notable advancement treatment, holding promise more targeted effective strategies.

Language: Английский

Citations

0
Immune checkpoint B7-H3 is a potential therapeutic target in prostate cancer DOI Creative Commons
Qi Shen, Kaichen Zhou, Hui‐qin Lu

et al.

Discover Oncology, Journal Year: 2024, Volume and Issue: 15(1)

Published: Dec. 22, 2024

High expression of immune checkpoint molecule B7-H3 (CD276) in many cancer types makes it a promising immunotherapeutic target. Both coinhibitory and costimulatory effects tumors have been demonstrated, but the mechanism response under dual is open to question. crucially involved migration invasion, angiogenesis, metabolism chemotherapy resistance prostate cancer. In addition potential on tumor environment, plays non-immune-mediated role progression. this review, we summarize current understanding molecular discuss as novel therapeutic target for

Language: Английский

Citations

0
Synergistic effects of immunotherapy and adjunctive therapies in prostate cancer management DOI Creative Commons
Jie Chen,

Na Ma,

Bo Chen

et al.

Critical Reviews in Oncology/Hematology, Journal Year: 2024, Volume and Issue: 207, P. 104604 - 104604

Published: Dec. 26, 2024

In recent years, cancer immunotherapy has received widespread attention due to significant tumor clearance in some malignancies. Various approaches, including vaccines, immune checkpoint inhibitors, oncolytic virotherapy, bispecific T cell engagers, and adoptive transfer, have completed or are undergoing clinical trials for prostate cancer. Despite blockade's extraordinary effectiveness treating a variety of cancers, targeted treatment using the system is still its infancy. Multiple factors heterogeneity cancer, cold microenvironment, low level neoantigens, contribute poor response. Significant effort being devoted improving immune-based therapy. Recently, several key discoveries demonstrate that agents may be used promise better prognosis patients as part combination strategies with other targeting tumor-associated mechanism resistance. Here, this review comprehensively examines advancements exploring potential synergistic effects when combined modalities enhance efficacy.

Language: Английский

Citations

0